PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27246695-11 2016 In vitro study revealed that AMPK activation using AICAR or mTOR inhibition using rapamycin effectively negated the beneficial cardiomyocyte mechanical effects of TLR4 inhibition (CLI-095) against paraquat toxicity, supporting a permissive role for AMPK-mTOR in TLR4 inhibition-offered cardioprotection against paraquat. Sirolimus 82-91 toll-like receptor 4 Mus musculus 163-167 32072192-9 2020 Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality. Sirolimus 178-187 toll-like receptor 4 Mus musculus 98-103 26888095-0 2016 Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice. Sirolimus 0-9 toll-like receptor 4 Mus musculus 50-53 19131641-3 2009 To examine these issues, we determined the effects of rapamycin-induced inhibition of mTORC1 on TLR2- and TLR4-induced neutrophil activation. Sirolimus 54-63 toll-like receptor 4 Mus musculus 106-110 19879295-5 2010 Low dose rapamycin-treatment of TLR4(-/-) recipients induced permanent engraftment of 45% islet graft (p=0.005) compared to WT recipients. Sirolimus 9-18 toll-like receptor 4 Mus musculus 32-36 24902807-9 2015 Importantly, pretreatment with 3-methyladenine (autophagy inhibitor) enhanced while rapamycin (autophagy inducer) decreased the expression of LOX-1, TLR4, and P-P38 MAPK. Sirolimus 84-93 toll-like receptor 4 Mus musculus 149-153 24950765-7 2015 Rapamycin treatment reduced the left ventricular ejection fraction to 23.5% (P < .05), and the collagen volume fraction of the ISO and ISO plus rapamycin groups was 5.9% and 25.9%, respectively, in TLR4 KO mice. Sirolimus 0-9 toll-like receptor 4 Mus musculus 201-205 24950765-8 2015 Compared with the WT mice, Beclin 1 and autophagy were downregulated in TLR4 KO mice (P < .05); however, the ISO plus rapamycin group had higher autophagy activity than did the ISO group in TLR4 KO mice (P < .05). Sirolimus 121-130 toll-like receptor 4 Mus musculus 193-197 22062220-7 2012 Rapamycin, an autophagy activator, reversed the effects of TLR4 antagonism. Sirolimus 0-9 toll-like receptor 4 Mus musculus 59-63 19285553-0 2009 Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression. Sirolimus 160-169 toll-like receptor 4 Mus musculus 82-85 19285553-0 2009 Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression. Sirolimus 160-169 toll-like receptor 4 Mus musculus 173-176 19285553-5 2009 Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity. Sirolimus 0-9 toll-like receptor 4 Mus musculus 28-31 34780278-10 2022 SP-A-induced activation of mechanistic target of rapamycin complex 1 (mTORC1) kinase requires beta-arrestin2 and is critically involved in degradation of LPS-induced TLR4. Sirolimus 49-58 toll-like receptor 4 Mus musculus 166-170 15967420-5 2005 In a separate experiment, rapamycin (2 mg/kg, daily) was administered to TLR4-deficient mice and WT mice immediately following aortic banding. Sirolimus 26-35 toll-like receptor 4 Mus musculus 73-77